The global emergence of Chikungunya infection: An integrated view

Rev Med Virol. 2022 May;32(3):e2287. doi: 10.1002/rmv.2287. Epub 2021 Aug 24.

Abstract

Chikungunya virus (CHIKV) is one of the emerging viruses around the globe. It belongs to the family Togaviridae and genus Alphavirus and is an arthropod borne virus that transmits by the bite of an infected mosquito, mainly through Aedes aegypti and Aedes albopcitus. It is a spherical, enveloped virus with positive single stranded RNA genome. It was first discovered during 1952-53 in Tanganyika, after which outbreaks were documented in many regions of the world. CHIKV has two transmission cycles; an enzootic sylvatic cycle and an urban cycle. CHIKV genome contains 11,900 nucleotides and two open reading frames and shows great sequence variability. Molecular mechanisms of virus host-cell interactions and the pathogenesis of disease are not fully understood. The disease involves three phases; acute, post-acute and chronic with symptoms including high-grade fever, arthralgia, macupapular rashes and headache. There is no licensed vaccine or specific treatment for CHIKV infection. This lack of specific interventions combined with difficulties in making a precise diagnosis together make the disease difficult to manage. In this review we aim to present the current knowledge of global epidemiology, transmission, structure, various aspects of diagnosis as well as highlight potential antiviral drugs and vaccines against CHIKV.

Keywords: Aedes aegypti; Aedes albopictus; Chikungunya virus; alpha virus.

Publication types

  • Review

MeSH terms

  • Aedes*
  • Animals
  • Antiviral Agents
  • Chikungunya Fever* / pathology
  • Chikungunya virus* / genetics
  • Disease Outbreaks
  • Humans

Substances

  • Antiviral Agents